Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406730 | 0.87 | USP2 (0.64) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL27912637 | 0.85 | TSHR (0.68) | USP2TSHRLMNAKDM4EALDH1A1 | |
| Busulfan SCHEMBL21456804 | 0.84 | TSHR (0.65) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL15530094 | 0.82 | LMNA (0.50) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL19755619 | 0.80 | LMNA (0.48) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL17615995 | 0.80 | LMNA (0.48) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL30009374 | 0.80 | TSHR (0.48) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL317051 | 0.80 | USP2 (0.52) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL164302 | 0.80 | USP2 (0.60) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL759445 | 0.79 | LMNA (0.36) | USP2TSHRLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119559-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BeiGene, Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| US-10351559-B2 | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | BEIGENE, LTD. (KY) | 2019-07-16 | — | — | US | disclosed |
| US-20180127412-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BEONE MEDICINES I GMBH (CH) | 2018-05-10 | — | — | US | disclosed |
| EP-3283486-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BeiGene, Ltd. (KY) | 2018-02-21 | — | — | EP | disclosed |
| US-9551931-B2 | Method of forming pattern, actinic-ray- or radiation-sensitive resin composition, actinic-ray- or radiation-sensitive film, process for manufacturing electronic device and electronic device | FUJIFILM CORPORATION (JP) | 2017-01-24 | — | — | US | disclosed |
| WO-2016165626-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BEIGENE, LTD. (KY) | 2016-10-20 | — | — | WO | disclosed |
| US-9250519-B2 | Pattern forming method and actinic ray-sensitive or radiation-sensitive resin composition for use in the method | FUJIFILM CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20160004157-A1 | METHOD OF FORMING PATTERN, ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC-RAY- OR RADIATION-SENSITIVE FILM, PROCESS FOR MANUFACTURING ELECTRONIC DEVICE AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
| US-9213237-B2 | Pattern forming method, actinic ray-sensitive or radiation-sensitive resin composition, resist film, manufacturing method of electronic device, and electronic device | FUJIFILM CORPORATION (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150331314-A1 | PATTERN FORMING METHOD, COMPOUND USED THEREIN, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| US-6736954-B2 | A METAL PLATING BATH COMPRISING METAL SALTS AND AN ADDITIVE CONSUMPTION INHIBITOR(A HETEROATOM ORGANIC COMPOUNDS WHICH MAY CONTAIN SULFUR, OXYGEN OR NITROGEN HETEROATOMS) IMPROVE THE BRIGHTNESS OF PLATED METAL AS WELL AS THE DUCTILITY | SHIPLEY COMPANY, L.L.C. | 2004-05-18 | — | — | US | disclosed |
| WO-2004011002-A1 | SUSTAINED-RELEASE TABLET COMPOSITION COMPRISING A DOPAMINE RECEPTOR AGONIST | PHARMACIA CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1308540-A1 | Plating bath and method for depositing a metal layer on a substrate | Shipley Co. L.L.C. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030070934-A1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY COMPANY, L.L.C. | 2003-04-17 | — | — | US | disclosed |
| US-5262563-A | Process for producing sulfoalkyl-substituted hydroxylamines | FUJI PHOTO FILM CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| US-5248811-A | Process for producing sulfoalkyl-substituted hydroxylamines | FUJI PHOTO FILM CO., LTD. (JP) | 1993-09-28 | — | — | US | disclosed |
| EP-0160252-B1 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1992-08-26 | — | — | EP | disclosed |
| EP-0410375-A1 | Process for producing sulfoalkyl-substituted hydroxylamines | FUJI PHOTO FILM CO., LTD. (JP) | 1991-01-30 | — | — | EP | disclosed |
| EP-0164122-A2 | Cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0164113-A2 | 3-pyrazolo(1,5-a)pyridinium cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351559-B2 | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | BRAF, RAF1, NRAS | USP2 3584/4885TSHR 2152/4885LMNA 1435/4885 |
| US-20150331314-A1 | PATTERN FORMING METHOD, COMPOUND USED THEREIN, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | RER1, CROCC, RFT1 | USP2 4202/4885TSHR 2809/4885LMNA 1586/4885 |
| US-20180127412-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BRAF, RAF1, NRAS | USP2 3584/4885TSHR 2152/4885LMNA 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.